These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 9667067)

  • 1. Differential effect of azidothymidine on resting and activated cells: potentiality of this drug for treatment of post-transfusion graft-versus-host disease.
    Nishimura M; Hidaka N; Akaza T; Tadokoro K; Juji T
    Res Commun Mol Pathol Pharmacol; 1998 May; 100(2):131-8. PubMed ID: 9667067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CTL clones isolated from an HLA-Cw-mismatched bone marrow transplant recipient with acute graft-versus-host disease.
    Sugimoto K; Murata M; Terakura S; Naoe T
    J Immunol; 2009 Nov; 183(9):5991-8. PubMed ID: 19812210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production.
    Shustov A; Nguyen P; Finkelman F; Elkon KB; Via CS
    J Immunol; 1998 Sep; 161(6):2848-55. PubMed ID: 9743345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The flavonoid Kaempferol suppresses the graft-versus-host reaction by inhibiting type 1 cytokine production and CD8+ T cell engraftment.
    Okamoto I; Iwaki K; Koya-Miyata S; Tanimoto T; Kohno K; Ikeda M; Kurimoto M
    Clin Immunol; 2002 May; 103(2):132-44. PubMed ID: 12027418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion.
    Orsini E; Bellucci R; Alyea EP; Schlossman R; Canning C; McLaughlin S; Ghia P; Anderson KC; Ritz J
    Cancer Res; 2003 May; 63(10):2561-8. PubMed ID: 12750280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells.
    Zorn E; Wang KS; Hochberg EP; Canning C; Alyea EP; Soiffer RJ; Ritz J
    Clin Cancer Res; 2002 Jul; 8(7):2052-60. PubMed ID: 12114403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutting edge: sustained expansion of CD8+ T cells requires CD154 expression by Th cells in acute graft versus host disease.
    Buhlmann JE; Gonzalez M; Ginther B; Panoskaltsis-Mortari A; Blazar BR; Greiner DL; Rossini AA; Flavell R; Noelle RJ
    J Immunol; 1999 Apr; 162(8):4373-6. PubMed ID: 10201970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-retroviral therapy in HIV-infected patients: in vitro effects of AZT and saquinavir on the response of CD4 and CD8 lymphocytes to interleukin-7.
    Beq S; Bugault F; Colle JH; Lambotte O; Delfraissy JF; Thèze J
    Eur Cytokine Netw; 2005 Dec; 16(4):293-9. PubMed ID: 16464744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of alloreactive anti-leukemic cytotoxic T lymphocytes with attenuated GVHD properties from haploidentical parents in childhood acute lymphoblastic leukemia.
    Jurickova I; Waller EK; Yeager AM; Boyer MW
    Bone Marrow Transplant; 2002 Nov; 30(10):687-97. PubMed ID: 12420208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytolytic effector mechanisms and gene expression in autologous graft-versus-host disease: distinct roles of perforin and Fas ligand.
    Miura Y; Thoburn CJ; Bright EC; Hess AD
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):156-70. PubMed ID: 14993881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
    Drobyski WR; Majewski D; Ozker K; Hanson G
    J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR; Majewski D; Hanson G
    Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary human keratinocytes as targets in predicting acute graft-versus-host disease following HLA-identical bone marrow transplantation.
    van Dijk AM; Kessler FL; Verdonck LF; Stadhouders-Keet SA; van Lier RA; de Gast GC; Otten HG
    Br J Haematol; 2000 Dec; 111(3):791-6. PubMed ID: 11122139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Large-scale preparation of human anti-third-party veto cytotoxic T lymphocytes depleted of graft-versus-host reactivity: a new source for graft facilitating cells in bone marrow transplantation.
    Aviner S; Yao X; Krauthgamer R; Gan Y; Goren-Arbel R; Klein T; Tabilio A; McMannis JD; Champlin R; Martelli MF; Bachar-Lustig E; Reisner Y
    Hum Immunol; 2005 Jun; 66(6):644-52. PubMed ID: 15993710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory T-cell suppression of CD8+ T-cell-mediated graft-versus-host reaction requires their presence during priming.
    Wang XN; Haniffa MA; Holtick U; Collin MP; Jackson G; Hilkens CM; Holler E; Edinger M; Hoffmann P; Dickinson AM
    Transplantation; 2009 Jul; 88(2):188-97. PubMed ID: 19623013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
    Johnson BD; Becker EE; Truitt RL
    Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
    Johnson BD; Becker EE; LaBelle JL; Truitt RL
    J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of post transfusion graft-versus-host disease.
    Juji T; Nishimura M; Tadokoro K
    Vox Sang; 2000; 78 Suppl 2():277-9. PubMed ID: 10938969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
    Jones SC; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.